Pharmacokinetics of the antitumor antibiotic n-pentyl-sparsomycin in beagle dogs

✍ Scribed by Zbigniew Zylicz; D. J. Theo Wagener; Marina Garzotto; Tom B. Vree; Eppo Kleijn; Leon A. G. M. Broek; Harry C. J. Ottenheijm

• Publisher: Springer US
• Year: 1990
• Tongue: English
• Weight: 524 KB
• Volume: 8
• Category: Article
• ISSN: 0167-6997
• DOI: 10.1007/bf00216921

✦ Synopsis

N-pentyl-sparsomycin (PSm) is a lipophilic analogue of sparsomycin (Sm), which is a well known inhibitor of protein synthesis. This compound was selected for preclinical pharmacokinetic studies because of its high in vitro and in vivo antitumor activity. In this study in which the drug was evaluated in beagle dogs under anaesthesia, the drug concentrations in plasma, urine and bile samples were determined using high performance liquid chromatography (HPLC). Plasma protein binding was approximately 54%. The mean t1/2 beta was 0.2 hours (12 minutes) and t1/2 tau was 0.75 +/- 0.1 hours (45 +/- 6 minutes). During continuous infusions up to 5.25 hours, the steady state was reached in 3 out of 6 experiments, suggesting that in some cases the real t1/2 tau was longer than measured. PSm was actively reabsorbed from the renal tubuli. This process was saturable at the higher doses. Tubular reabsorption played only a minor role in pharmacokinetics as most of the drug (67%) was eliminated by the non-renal clearance. The non-renal clearance was saturable at higher doses of PSm and was the reason for non-linearity of pharmacokinetics.